Business Context and Reporting Period
Company: cbdMD, Inc. (formerly Level Brands, Inc.)
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: September 30, 2024
Business Overview: cbdMD operates nationally recognized CBD brands (cbdMD, Paw CBD) and the functional mushroom brand ATRx Labs. The company focuses on hemp-derived dietary supplements, topicals, and beverages, distributed primarily through e-commerce (approx. 80% of sales) and wholesale channels. The company is a non-accelerated filer and a smaller reporting company.
Key Financial Metrics (Fiscal Year 2024)
| Metric | Fiscal 2024 | Fiscal 2023 |
|---|---|---|
| Total Net Sales | $19.48 million | $24.16 million |
| Gross Profit | $12.00 million (61.6% margin) | $14.98 million (62.0% margin) |
| Operating Loss | $(3.32) million | $(22.49) million |
| Net Loss | $(3.70) million | $(22.94) million |
| Net Loss Attributable to Common Shareholders | $(7.70) million | $(26.94) million |
| Cash and Cash Equivalents (Sept 30, 2024) | $2.45 million | $1.80 million |
| Working Capital | $(1.1) million (Deficit) | $3.4 million |
| Convertible Notes Outstanding (Principal) | ~$1.03 million | $0 |
| Accrued Preferred Dividends | $4.67 million | $0.67 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 19% ($4.7 million) year-over-year. Both e-commerce and wholesale channels declined by approximately 19%, attributed to macro inflationary pressures, reduced marketing spend, and regulatory headwinds.
- Improved Operating Loss: GAAP operating loss improved significantly by $19.2 million compared to fiscal 2023. This improvement is largely due to the absence of a $13.2 million goodwill and intangible asset impairment charge recorded in fiscal 2023.
- Cost Rationalization: Operating expenses decreased by $8.9 million (36.4%), driven by a $2.8 million reduction in marketing spend and a $1.9 million reduction in payroll expenses.
- Liquidity Deterioration: Working capital shifted from a positive $3.4 million in 2023 to a negative $1.1 million in 2024. This is primarily due to a $4.0 million increase in accrued dividends on Series A Preferred Stock, which were suspended in August 2023.
- Inventory Write-down: The company recorded a one-time non-cash inventory write-down of approximately $588,000 in Q4 2024 related to obsolete/expired inventory and regulatory label changes.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook
- Path to Profitability: Management is focused on cost rationalization and launching new categories (ATRx functional mushrooms, hemp beverages) to drive revenue growth in fiscal 2025.
- Recent Developments: Q4 2024 revenue was impacted by email deliverability issues (~$200k impact) and international regulatory registration delays. Management anticipates a rebound in Q1 2025.
- Capital Structure: The company is actively seeking to simplify its capital structure, specifically regarding the 8% Series A Cumulative Convertible Preferred Stock, which currently hinders strategic acquisitions and new investment.
Material Risks and Contingencies
- Going Concern: The filing includes an "emphasis of matter" regarding substantial doubt about the company's ability to continue as a going concern within twelve months due to recurring losses and working capital deficits.
- Debt Maturity: Convertible Notes totaling approximately $364,000 (principal) mature on July 30, 2025. Repayment ability is uncertain without refinancing or conversion.
- Preferred Stock Dividends: The company is unable to pay cash dividends on its Series A Preferred Stock. Accrued dividends are compounding at approximately $1 million per quarter, increasing the liability.
- Listing Compliance: The company received notice from NYSE American regarding non-compliance with stockholders' equity requirements ($4 million minimum). A plan to regain compliance has been accepted with a deadline of December 5, 2025.
- Regulatory Environment: Ongoing uncertainty regarding FDA and FTC regulations on CBD products poses a risk to operations and marketing claims.
Investor Verification Checklist
- Cash Runway: Verify if the current cash balance of $2.45 million is sufficient to cover operations and debt obligations through July 2025 without additional financing.
- Preferred Stock Accruals: Monitor the growth of accrued dividends on Series A Preferred Stock, which currently exceed $4.6 million and reduce net income available to common shareholders.
- Debt Conversion: Track the conversion of outstanding Convertible Notes into common stock, which may cause significant dilution to existing shareholders.
- NYSE Compliance: Confirm progress on the plan to regain compliance with NYSE American listing standards to avoid delisting.
- Revenue Rebound: Validate management's expectation of revenue recovery in Q1 2025 following Q4 headwinds (email deliverability, international regulations).